Kaitlyn Bader, Senior Editor

KT-474 is a first-in-class, investigational IRAK4 degrader.

The approval of Galderma’s Restylane Eyelight was one of Martin’s top highlights of 2023.

Linda Stein Gold, MD, reviewed recent studies of various topical retinoids and their ability to decrease atrophic scars during the 2023 ARM Yourself With Knowledge webinar.

Baldwin reviewed inflammatory bowel disease, depression, and pregnancy during the 2023 ARM Yourself With Knowledge webinar.

The collaboration, named ARTIBAND, will extend over a 3-year period

2023 was full of advancements in both medical and cosmetic dermatology, and 2024 is shaping up to be just as exciting.

ICYMI, this week we had articles about the FDA granting priority review of Abeona's pz-cel BLA for recessive DEB, end-of-the-month highlights from the November issue and supplement of Dermatology Times, the FDA accepting Arcutis' sNDA of roflumilast cream 0.15% for AD, and more.

The US license period will start on February 22, 2025.

Learn more about the in-depth topics covered in the November 2023 Frontline Forum corticosteroid-responsive dermatoses supplement of Dermatology Times.

Learn more about the in-depth topics covered in the November 2023 print issue of Dermatology Times.

The FDA’s PDUFA target date is May 25, 2024.

ICYMI, this week we had articles about KT-474 efficacy in atopic dermatitis and hidradenitis suppurativa, endoscopic thoracic sympathectomy surgery for hyperhidrosis, and new data on rademikibart for atopic dermatitis.

Patient Cole Villaflor, his mother, and Michael Levy, MD, PhD, provide insights into Cole’s hyperhidrosis diagnosis and subsequent endoscopic thoracic sympathectomy surgery.

From the November cover: Raj Chovatiya, MD, PhD, and Lawrence Eichenfield, MD, shared their insights and key treatment pearls into atopic dermatitis management for adults and children.

This week’s collection of the latest dermatologic studies covers the relationship between melanoma pigmentation and inflammatory cytokines, the negative use of topical nystatin for tinea infections, the association between psoriasis and schizophrenia, and the association between pediatric atopic dermatitis and cardiovascular risk factors.

ICYMI, this week we had articles about coverage from the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting, the availability of UCB's bimekizumab, FDA breakthrough therapy designation to QTORIN rapamycin for microcystic lymphatic malformations, and more.

Kwatra presented on the unmet need for itch improvement in patients with skin of color.

This week’s collection of the latest dermatologic studies covers atypical molluscum contagiosum lesions with a CD30-positive T-cell lymphoid infiltrate, comorbidities in pediatric psoriasis, tralokinumab for adolescents with severe AD, and intralesional bleomycin combined with lidocaine for recalcitrant keloid scars.

ICYMI, this week we had articles about a proposed ban of formaldehyde in hair relaxers, TAK-279 for psoriatic arthritis, and updated atopic dermatitis guidelines from AAD.

Shawn Kwatra, MD, shares his thoughts on the positive phase 3 data of OLYMPIA 2.

Catch up on the best highlights from Maui Derm NP + PA Fall, Inflammatory Disease Summit, and SDPA Fall.

Data from Novartis will be presented at the 2023 American College of Allergy, Asthma, and Immunology Scientific Meeting.

Catch up on the best highlights from Fall Clinical for PAs & NPs, SDPA Summer, and Maui Derm NP + PA Summer.

The guidelines update AAD’s 2014 recommendations for the management of AD with phototherapy and systemic therapies.

Kwatra discussed his research team’s findings published in JAMA Dermatology.

New technologies such as the 1726-nm laser and pneumatic assisted broad band light are emerging treatments in acne.

Click here to answer this week's NP & PA poll. Out of the meetings listed below, which one did you enjoy the most?

Christopher Bunick, MD, PhD, and David Light, CEO of Valisure, weigh in on the proposed formaldehyde ban.

Study results were presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.

ICYMI, this week we had articles about World Psoriasis Day, the FDA approval of secukinumab for hidradenitis suppurativa, positive data of delgocitinib cream for chronic hand eczema, and more.